The Use of Psychotropic Medication for People with Severe Disabilities and Challenging Behavior: Current Status and Future Directions

Research and Practice for Persons with Severe Disabilities

Volumn 23, Issue 2, 1998, Pages 83-97

  Kennedy, Craig H ^a   Meyer, Kim A ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

behavioral pharmacology; challenging behavior; developmental disabilities; psychotropic medication

Indexed keywords

EID: 0032089387     PISSN: 15407969     EISSN: 21692408     Source Type: Journal    
DOI: 10.2511/rpsd.23.2.83     Document Type: Article

References (161)

1. Aman M. G. van Bourgondien M. E. Osborne P. W. Sarphare G. (1997). Side effects associated with psychoactive medication in individuals with autism. Journal of Autism and Developmental Disorders, 27, 342–344.
2. Aman M. G. Pejeau C. Osborne P. Rojahn J. Handen B. (1996). Four-year follow-up of children with low intelligence and ADHD. Research in Developmental Disabilities, 17, 417–432.
3. Aman M. G. Singh N. N. (1982). Methylphenidate in severely retarded residents and the clinical significance of stereotypic behavior. Applied Research in Mental Retardation, 3, 345–358.
4. Aman M. G. Singh N. N. (1983). Pharmacological intervention. In Ed. Matson J. L. Mulick J. A. (Eds.), Handbook of mental retardation (pp. 317–337). New York: Pergammon Press.
5. Aman M. G. Singh N. N. (1988). Patterns of drug use, methodological considerations, measurement techniques, and future trends. In Ed. Aman M. G. Singh N. N. (Eds.), Psychopharmacology of the developmental disabilities (pp. 1–28). New York: Springer-Verlag.
6. Aman M. G. Teehan C. J. White A. J. Turbott S. H. Vaithianathan C. (1989). Haloperidol treatment with chronically medicated residents: Do effects on clinical behavior and reinforcement contingencies. American Journal of Mental Deficiency, 93, 452–460.
7. Baer D. M. (1979). Temporal lobe epilepsy: A syndrome of sensory-limbic hyperconnection. Cortex, 15, 357–384.
8. Baldessarini R. J. (1985). Drugs and treatment of psychiatric disorders. In Ed. Gilman A. G. Goodman L. S. Ralle T. W. Murad F. (Eds.), The pharmacological basis of therapeutics (pp. 387–395). New York: Macmillan.
9. Barrett J. E. Sanger D. J. (1991). Behavioral pharmacology in the era of neuroscience. Journal of the Experimental Analysis of Behavior, 56, 167–169.
10. Barrett J. E. Hoffman S. M. (1991). Neurochemical changes correlated with behavior maintained under fixed-interval and fixed-ratio schedules of reinforcement. Journal of the Experimental Analysis of Behavior, 56, 395–406.
11. Baumeister A. A. Sevin J. A. (1990). Pharmacologic control of aberrant behavior in the mentally retarded: Toward a more rational approach. Neuroscience and Biobehavioral Reviews, 14, 253–262.
12. Benjamin E. Buot-Smith T. (1993). Naltrexone and fluoxetine in Prader-Willi syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 870–873.
13. Bernstein G. A. Hughes J. R. Mitchell J. E. Thompson T. (1987). Effects of narcotic antagonists on self-injurious behavior: A single case study. Journal of the American Academy of Child and Adolescent Psychiatry, 26, 886–889.
14. Bickel W. K. Higgins S. T. Griffiths R. R. (1989). Repeated diazepam administration: Effects on the acquisition and performance of response chains in humans. Journal of the Experimental Analysis of Behavior, 52, 47–56.
15. Bickel W. K. Higgins S. T. Hughes J. R. (1991). The effects of diazepam and triazolam on repeated acquisition and performance of response sequences with an observing response. Journal of the Experimental Analysis of Behavior, 56, 217–237.
16. Bindra D. Anchel H. (1963). Immobility as an avoidance response, and its disruption by drugs. Journal of the Experimental Analysis of Behavior, 6, 213–218.
17. Bisconer S. W. Zhang X. Sine L. F. (1996). Impact of a psychotropic medication and physical restraint review process on adults with mental retardation, psychiatric diagnoses, and challenging behaviors. Journal of Developmental and Physical Disabilities.
18. Bordi F. Matthews T. J. (1990). Effects of D-amphetamine, diazepam, and pentobarbital on the schedule-controlled pecking and locomotor activity of pigeons. Journal of the Experimental Analysis of Behavior, 53, 87–102.
19. Brady J. V. (1956). Assessment of drug effects on emotional behavior. Science, 123, 1033–1034.
20. Cameron O. G. Appel J. B. (1972). Conditioned suppression of bar-pressing behavior by stimuli associated with drugs. Journal of the Experimental Analysis of Behavior, 17, 127–137.
21. Carr E. G. Durand V. M. (1985). Reducing behavior problems through functional communication training. Journal of Applied Behavior Analysis, 18, 111–126.
22. Chandler M. Gaultieri C. T. Fahs J. J. (1988). Other psychotropic drugs: Stimulants, antidepressants, the anxiolytics, and lithium carbonate. In Ed. Aman M. G. Singh N. N. (Eds.), Psychopharmacology of the developmental disabilities (pp. 119–145). New York: Springer-Verlag.
23. Coccaro E. F. (1992). Impulsive aggression and central serotoninergic system function in humans. International Clinical Psychopharmacology, 7, 3–12.
24. Cohen S. L. (1986). A pharmacological examination of the resistance-to-chance hypothesis of response strength. Journal of the Experimental Analysis of Behavior, 46, 363–379.
25. Cook L. Catania A. C. (1964). Effects of drugs on avoidance and escape behavior. Federation Proceedings, 23, 818–835.
26. Copper L. J. Wacker D. P. Thursby D. Plagmann L. A. Harding J. Derby K. M. (1992). Using parents as therapists to evaluate the appropriate behavior of their children: Application to a tertiary diagnostic clinic. Journal of Applied Behavior Analysis, 23, 285–296.
27. Corbett J. A. Trimble M. R. Nichol T. C. (1985). Behavioral and cognitive impairments in children with epilepsy: The long-term effects of anticonvulsant therapy. Journal of the American Association of Child Psychiatry, 24, 17–23.
28. Courvosier S. (1956). Pharmacodynamic basis for the use of chlorpromazine in psychiatry. Journal of Clinical and Experimental Psychopathology, 17, 25–37.
29. Craft M. (1957). Tranquilizers in mental deficiency: Chlorpromazine. Journal of Mental Deficiency Research, 1, 91–97.
30. Craft M. Ismail I. A. Krishnamurti D. Mathews J. Regan A. Seth R. V. North P. M. (1987). Lithium in the treatment of aggression in mentally handicapped patients. British Journal of Psychiatry, 150, 685–689.
31. Davidson A. B. Weidley E. (1976). Differential effects of neuroleptics and other psychotropic agents on acquisition of avoidance in rats. Life Science, 18, 1279–1284.
32. Davis K. V. Sprague R. L. Werry J. S. (1969). Stereotyped behavior and activity level in severe retardates: The effect of drugs. American Journal of Mental Deficiency, 73, 721–727.
33. Dews P. B. (1955). Studies of behavior. I. Differential sensitivity to pentobarbital of pecking performance in pigeons depending on the schedule of reward. Journal of Pharmacology and Experimental Therapeutics, 113, 393–401.
34. Dews P. B. (1958 a). Studies of behavior. IV. Stimulant actions of methamphetamine. Journal of Pharmacology and Experimental Therapeutics, 122, 137–147.
35. Dews P. B. (1958 b). Effects of chlorpromazine and promazine on performance on a mixed schedule of reinforcement. Journal of the Experimental Analysis of Behavior, 1, 73–82.
36. DiMascio A. Shader R. I. Harmatz J. (1967). Psychotropic drugs and induced hostility. Psychosomatics, 10, 46–47.
37. Ellis C. R. Singh Y. N. Singh N. N. (1997). Use of behavior-modifying drugs. In Ed. Singh N. N. (Ed.), Prevention and treatment of severe behavior problems: Models of methods in developmental disabilities (pp. 149–176). Pacific Grove, CA: Brooks/Cole.
38. Evans R. W. Clay T. H. Gaultieri C. T. (1987). Carbamazepine in pediatric psychiatry. Journal of the American Academy of Child and Adolescent Psychiatry, 26, 2–8.
39. Field C. J. Aman M. G. White A. J. Vaithianathan C. (1986). A single-subject study of imipramine in a mentally retarded woman with depressive symptoms. Journal of Mental Deficiency Research, 30, 191–198.
40. Fredericks D. W. Hayes L. J. (1995). Effects of drug changes and physician prescribing practices on the behavior of persons with mental retardation. Journal of Developmental and Physical Disabilities, 7, 105–122.
41. Gadow K. D. Poling A. D. (1988). Pharmacotherapy and mental retardation. Boston: Little, Brown, & Company.
42. Galizio M. Allen A. R. (1991). Variable-ratio schedules of timeout from avoidance: Effects of D-amphetamine and morphine. Journal of the Experimental Analysis of Behavior, 56, 193–204.
43. Gardos G. (1980). Disinhibition of behavior by antianxiety drugs. Psychosomatics, 21, 1025–1026.
44. Gaultieri C. T. Keppel J. M. (1985). Psychopharmacology in the mentally retarded and a few related issues. Psychopharmacology Bulletin, 21, 304–309.
45. Gay P. E. (1984). Effects of antiepileptic drugs and seizure type on operant responding in mentally retarded persons. Epilepsia, 25, 377–386.
46. Geller I. Seifter J. (1960). The effects of meprobamate, barbiturates, D-amphetamine and promazine on experimentally induced conflict in the rat. Pscyhopharmacologia, 1, 482–492.
47. Goldberg J. R. Kurland A. A. (1970). Dilantin treatment of hospitalised cultural-familial retardates. Journal of Nervous and Mental Disease, 150, 133–137.
48. Golden G. S. (1988). Tardive dyskinesia and developmental disabilities. In Ed. Aman M. G. Singh N. N. (Eds.), Psychopharmacology of the developmental disabilities (pp. 197–215). New York: Springer-Verlag.
49. Grossett D. L. Williams D. E. (1988). Psychopharmacological intervention for the treatment of self-injurious behavior in a person with profound mental retardation and a psychiatric disorder. Paper presented at the annual meeting of the Association for Behavior Analysis conference, Philadelphia, PA.
50. Haddad P. (1997). Newer antidepressants and the discontinuation syndrome. Journal of Clinical Psychiatry, 58, 17–21.
51. Hasan M. K. Mooney R. P. (1979). Three cases of manic/depressive illness in mentally retarded adults. American Journal of Psychiatry, 36, 1069–1071.
52. Hearst E. (1960). Multiple schedules of time-correlated reinforcement. Journal of the Experimental Analysis of Behavior, 3, 49–62.
53. Heisse G. A. Boff E. (1962). Continuous avoidance as a base-line for measuring behavioral effects of drugs. Psychopharmacologia, 3, 264–282.
54. Hellings J. A. Warnock J. K. (1994). Self-injurious behavior and serotonin in Prader-Willi syndrome. Psychopharmacology Bulletin, 30, 245–250.
55. Hellings J. A. Kelley L. A. Gabrielli W. F. Kilgore E. Shah P. (1996). Sertraline response in adults with mental retardation and autistic disorder. Journal of Clinical Psychiatry, 57, 333–336.
56. Herr F. Stewart J. Charest M. P. (1961). Tranquilizers and antidepressants: A pharmacological comparison. Archives of International Pharmacodynamics, 134, 328–342.
57. Herrnstein R. J. (1959). Stereotypy of response during continuous and intermittent reinforcement. Journal of the Experimental Analysis of Behavior, 2, 267.
58. Herrnstein R. J. Morse W. H. (1956). Effects of pentobarbital on intermittently reinforced behavior. Science, 125, 929–931.
59. Heyman G. M. Monaghan M. M. (1987). Effects of changes in response requirement and deprivation on the parameters of the matching law equation: New data and review. Journal of Experimental Psychology: Animal Behavior Processes, 13, 384–394.
60. Hill B. K. Balow E. A. Bruininks R. H. (1985). A national survey of prescribed drugs in institutions and community residential facilities for mentally retarded people. Psychopharmacology Bulletin, 21, 279–284.
61. Horner R. H. Carr E. G. (1997). Behavioral support for students with severe disabilities: Functional assessment and comprehensive intervention. Journal of Special Education, 31, 84–104.
62. Horner R. H. Day H. M. Day J. R. (in press). Using neutralizing routines to reduce problem behaviors. Journal of Applied Behavior Analysis.
63. Huessy H. R. Ruoff P. A. (1984). Towards rational drug usage in a state institution for retarded individuals. Psychiatry Journal of the University of Ottawa, 9, 56–58.
64. Hymowitz N. (1981). Effects of diazepam on schedule-controlled and schedule-induced behavior under signaled and unsignaled shock. Journal of the Experimental Analysis of Behavior, 36, 119–132.
65. Insel T. R. Ninan P. T. Aloi J. Jimerson D. C. Skolnick P. Paul S. M. (1984). A benzodiazepine receptor-mediated model of anxiety. Archives of General Psychiatry, 41, 741–750.
66. Intagliata J. Rinck C. (1985). Psychoactive drug use in public and community residential facilities for mentally retarded persons. Psychophramacology Bulletin, 21, 268–278.
67. Janicak P. G. Davis J. M. Preskorn S. H. Ayd F. J. (1997). Principles and practice of psychopharmacotherapy (2nd ed.). Baltimore: Williams & Wilkins.
68. Jeffery D. R. Barrett J. E. (1979). Effects of chlordiazepoxide on comparable rates of punished and unpunished responding. Psychopharmacology, 64, 9–11.
69. Johnston J. M. Pennypacker H. S. (1993). Strategies and tactics of behavioral research (2nd ed.). Hillsdale, NJ: LEA.
70. Kalachnik J. E. Sprague R. L. (1994). How well do physicians, pharmacists, and psychologists assess tardive dyskinesia movements? Annals of Pharmacotherapy, 28, 185–190.
71. Kane J. M. Smith J. M. (1982). Tardive dyskinesia: Prevalence and risk factors, 1959–1979. Archives of General Psychiatry, 39, 473–481.
72. Kaufman K. R. Katz-Garris L. (1979). Epilepsy, mental retardation, and anitconvulsant therapy. American Journal of Mental Deficiency, 84, 256–259.
73. Kelleher R. T. Cook L. (1959). Effects of D-amphetamine, meprobamate, phenobarbital, mephenesin, or chlorpromazine on DRL and FR schedules of reinforcement. Journal of the Experimental Analysis of Behavior, 2, 267.
74. Kelleher R. T. Riddle W. C. Cook L. (1962). Observing responses in pigeons. Journal of the Experimental Analysis of Behavior, 5, 3–13.
75. Kennedy C. H. Itkonen T. (1993). Effects of setting events on the problem behavior of students with severe disabilities. Journal of Applied Behavior Analysis, 26, 321–327.
76. Kennedy C. H. Meyer K. A. (in press). Establishing operations and the motivation of problem behavior. In Ed. Luselli J. A. (Ed.), Antecedent approaches to the reduction of problem behavior. Baltimore: Paul H. Brookes.
77. Kennedy C. H. Meyer K. A. Werts M. G. Cushing L. S. (1998). Effects of sleep deprivation on avoidance responding. Manuscript submitted for publication.
78. LeVeck G. D. Buckley P. (1961). The use of psychopharmacologic agents in retarded children with behavior disorders. Journal of Chronic Diseases, 13, 174–183.
79. Lipman R. S. (1970). The use of psychopharmacological agents in residential facilities for the retarded. In Ed. Menolascino F. J. (Ed.), Psychiatric approaches to mental retardation (pp. 387–398). New York: Basic Books.
80. Lipman R. S. (1982). Psychotropic drugs in mental retardation: The known and the unknown. Advances in Learning and Behavioral Disabilities, 1, 261–282.
81. Livingston S. (1976). Behavioral effects of antiepileptic drugs. Developmental Medicine and Child Neurology, 18, 258–259.
82. MacDonald R. L. Kelly K. M. (1994). Mechanisms of action of currently prescribed and newly developed anticonvulsant drugs. Epilepsia, 35 (Suppl. 4), S41–S50.
83. Mace F. C. (1994). Basic research needed for stimulating the development of behavioral technologies. Journal of the Experimental Analysis of Behavior, 61, 529–550.
84. Marholin D. Touchette P. E. Stewart R. M. (1979). Withdrawal of chronic chlorpromazine medication: An experimental analysis. Journal of Applied Behavior Analysis, 12, 159–171.
85. Martin J. E. Agran M. (1985). Psychotropic and anticonvulsant drug use by mentally retarded adults across community residential and vocational placements. Applied Research in Mental Retardation, 6, 33–49.
86. Mattson R. H. (1996). The role of the old and the new antiepileptic drugs in special populations: Mental and multiple handicaps. Epilepsia, 37 (Suppl 6), S45–S53.
87. McAndrew J. B. Case Q. Treffert D. A. (1972). Effects of prolonged phenothiazine intake on psychotic and other hospitalized children. Journal of Autism and Childhood Schizophrenia, 2, 75–91.
88. McKearney J. W. (1970). Rate-dependent effects of drugs: Modification by discriminative stimuli of the effects of amo-barbital on schedule-controlled behavior. Journal of the Experimental Analysis of Behavior, 14, 167–175.
89. McMillan D. E. (1967). Comparison of the punishing effects of response-produced shock and response-produced timeout. Journal of the Experimental Analysis of Behavior, 10, 439–449.
90. Meyer L. H. Evans I. M. (1993). Meaningful outcomes in behavioral intervention: Evaluating positive approaches to the remediation of challenging behaviors. In Ed. Reichle J. Wacker D. P. (Eds.), Communicative approaches to the management of challenging behavior (pp. 407–428). Baltimore: Paul H. Brookes.
91. Michael J. L. (1982). Distinguishing between discriminative and motivational functions of stimuli. Journal of the Experimental Analysis of Behavior, 37, 149–155.
92. Millichamp C. J. Singh N. N. (1987). The effects of intermittent drug therapy on stereotypy and collateral behaviors of mentally retarded persons. Research in Developmental Disabilities, 8, 213–227.
93. Nakao K. Higashio T. Inukai T. (1985). Antagonism of picrotoxin against the taming effect of carbamazepine on fighting behavior in mice. Japanese Journal of Pharmacology, 39, 281–283.
94. Newland M. C. Marr M. J. (1985). The effects of chlorpromazine and imipramine on rate and stimulus control of matching to sample. Journal of the Experimental Analysis of Behavior, 44, 49–68.
95. O'Neill R. E. Horner R. H. Albin R. Sprague J. Storey K. (1990). Functional analysis of problem behavior: A practical assessment guide. Sycamore, IL: Sycamore Publishing.
96. O'Reilly M. F. (1995). Functional analysis and treatment of escape-maintained aggression correlated with sleep deprivation. Journal of Applied Behavior Analysis, 28, 225–226.
97. Ortiz A. Dabbagh M. Gershon S. (1984). Lithium: Clinical use, toxicology, and mode of action. In Ed. Bernstein J. C. (Ed.), Clinical psychopharmacology (pp. 111–144). Boston: John Wright.
98. Pary R. J. (1991 a). Towards defining adequate lithium trials for individuals with mental retardation and mental illness. American Journal on Mental Retardation, 95, 681–691.
99. Pary R. J. (1991 b). Side effects during lithium treatment for psychiatric disorders in adults with mental retardation. American Journal on Mental Retardation, 96, 269–273.
100. Paulson G. W. Rizvi C. A. Crane G. E. (1975). Tardive dyskinesia as a possible sequel of long-term therapy with phenothiazines. Clinical Pediatrics, 14, 953–955.
101. Pellock J. M. (1994). Standard approach to anticonvulsant drug treatment in the United States. Epilepsia, 35, 11–18.
102. Poindexter A. R. (1989). Psychotropic drug patterns in a large ICF/MR facility: A ten-year experience. American Journal of Mental Retardation, 93, 624–626.
103. Poling A. LeSage M. (1995). Evaluating psychotropic drugs in people with mental retardation: Where are the social validity data? American Journal of Mental Retardation, 100, 193–200.
104. Post M. Uhde T. W. (1986). Anticonvulsants in non-epileptic psychosis. In Ed. Trimble M. R. Bolweg T. G. (Eds.), Aspects of epilepsy and psychiatry (pp. 177–212). Chichester, UK: John Wiley & Sons.
105. Rapoport J. L. Mikkelsen E. J. (1978). Antidepressants. In Ed. Werry J. (Ed.), Pediatric psychopharmacology: The use of behavior modifying drugs in children (pp. 316–355). New York: Brunner/Mazel.
106. Rapport M. D. Sonis W. A. Fialkov M. J. Matson J. L. Kazdin A. E. (1983). Carbamazepine and behavior therapy for aggressive behavior. Behavior Modification, 7, 255–265.
107. Reid A. H. Naylor G. J. Kay D. S. G. (1981). A double-blind placebo-controlled, crossover trial of carbamazepine in overactive severely mentally handicapped patients. Psychological Medicine, 11, 109–113.
108. Richardson J. S. Zaleski W. A. (1986). Endogenous opiates and self-mutilation. American Journal of Psychiatry, 143, 939.
109. Richelle M. (1969). Combined action of diazepam and d-amphetamine on fixed-interval performance in cats. Journal of the Experimental Analysis of Behavior, 12, 989–998.
110. Ross G. S. Hodos W. Brady J. V. (1962). Electroencephalographic correlates of temporally spaced responding and avoidance behavior. Journal of the Experimental Analysis of Behavior, 5, 467–479.
111. Sandman C. A. Barron J. Colman H. (1990). An orally administered opiate blocker, naltrexone, attenuates self-injurious behavior. American Journal on Mental Retardation, 95, 93–102.
112. Schaal D. W. Hackenberg T. (1994). Toward a functional analysis of drug treatment for behavior problems of people with developmental disabilities. American Journal on Mental Retardation, 99, 113–140.
113. Schroeder S. R. (1988). Neuroleptic medications for persons with developmental disabilities. In Ed. Aman M. G. Singh N. N. (Eds.), Psychopharmacology of the developmental disabilities (pp. 82–100). New York: Springer-Verlag.
114. Schroeder S. R. Bickell W. Richmond G. (1986). Primary and secondary prevention of self-injurious behavior. In Ed. Gadow K. (Ed.), Advances in learning and behavioral disabilities (pp. 65–87). Greenwich, CT: JAI Press.
115. Schroeder S. R. Gaultieri C. T. (1985). Behavioral interactions induced by chronic neuroleptic therapy in persons with mental retardation. Psychopharmacology Bulletin, 21, 310–315.
116. Schroeder S. R. Rojahn J. Hawk B. Kanoy R. C. Thios S. J. Mulick J. A. Stephens M. (1982). Environmental antecedents which affect management and maintenance of programs for self-injurious behavior. In Ed. Hollies J. H. Meyers C. E. (Eds.), Life-threatening behaviors: Analysis and intervention (pp. 105–159). Washington, DC: American Association on Mental Retardation.
117. Shaikh M. B. Edinger H. M. Siegel A. (1988). Carbamazepine regulates feline aggression elicited from the midbrain periaqueductal gray. Pharmacology, Biochemistry, and Behavior, 30, 409–415.
118. Sheard M. H. (1984). Clinical pharmacology of aggressive behavior. Clinical Neuropharmacology, 7, 173–183.
119. Shields W. D. (1994). Investigational antiepileptic drugs for the treatment of childhood seizure disorders: A review of efficacy and safety. Epilepsia, 35 (Suppl. 2), S24–S29.
120. Sidley N. A. Schoenfeld W. N. (1963). Effects of chlorpromazine and d-amphetamine on escape and avoidance behavior under a temporally defined schedule of negative reinforcement. Journal of the Experimental Analysis of Behavior, 6, 293–295.
121. Sidman M. (1952). A note on functional relations obtained from group data. Psychological Bulletin, 49, 263–269.
122. Singh N. N. (in press). Cultural diversity: A challenge for evaluating systems of care. In Ed. Epstein M. H. Kutash K. Duchnowski A. (Eds.), Community-based programming for children with serious emotional disturbance and their families: Research and evaluation. Austin, TX: ProEd.
123. Singh N. N. Ellis C. R. Donatelli L. S. Williams D. E. Ricketts R. W. Goza A. B. Perlman N. Everly D. E. Best A. M. Singh Y. N. (1996). Professionals' perceptions of psychotropic medication in residential facilities for individuals with mental retardation. Journal of Intellectual Disability Research, 40, 1–7.
124. Singh N. N. Ellis C. R. Weschler H. (in press). Psychopharmacoepidemiology of mental retardation. Journal of Child and Adolescent Psychopharmacology.
125. Singh N. N. Sood A. Sonenklar N. Ellis C. R. (1991). Assessment and diagnosis of mental illness in persons with mental retardation: Methods and measures. Behavior Modification, 15, 419–443.
126. Singh N. N. Singh Y. N. Ellis C. R. (1992). Psychopharmacology of self-injury. In Ed. Luiselli J. K. Matson J. L. Singh N. N. (Eds.), Self-injurious behavior: Analysis, assessment, and treatment (pp. 307–351). New York: Springer-Verlag.
127. Singh N. N. Sood A. Sonenklar N. Ellis C. R. (1991). Assessment and diagnosis of mental illness in persons with mental retardation. Behavior Modification, 15, 419–443.
128. Singh N. N. Winton A. S. W. (1984). Behavioral monitoring of pharmacological interventions for self-injury. Applied Research in Mental Retardation, 5, 161–170.
129. Singh N. N. Winton A. S. W. (1989). Behavioral pharmacology. In Ed. Luiselli J. K. (Ed.), Behavioral medicine and developmental disabilities (pp. 152–179). New York: Springer-Verlag.
130. Skolnick P. Paul S. M. (1983). New concepts in the neurobiology of anxiety. Journal of Clinical Psychiatry, 44, 12–20.
131. Smith C. Smith M. Reynard A. M. (1992). Textbook of pharmacology. Philadelphia: W. B. Saunders Company.
132. Snyder S. H. (1981). Dopamine receptors, neuroleptics, and schizophrenia. American Journal of Psychiatry, 138, 460–464.
133. Soubrie P. (1988). Serotonin and behavior, with special regard to animal models of anxiety, depression, and waiting ability. In Ed. Osborne N. N. Hamon M. (Eds.), Neuronal serotonin (pp. 255–270). New York: John Wiley & Sons.
134. Sovner R. Hurley A. (1981). The management of chronic behavior disorders in mentally retarded adults with lithium carbonate. Journal of Nervous and Mental Disease, 169, 191–195.
135. Sprague R. L. (1977). Psychopharmacotherapy in children. In Ed. McMillan M. F. Hernao S. (Eds.), Child psychiatry: Treatment and research (pp. 130–149). New York: Brunner/Mazel.
136. Sprague R. L. Werry J. S. (1971). Methodology of psychopharmacological studies with the retarded. In Ed. Ellis N. (Ed.), International review of research in mental retardation (pp. 147–219). New York: Academic Press.
137. Stevenson R. D. Wolraich M. L. (1989). Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. Pediatric Clinics of North America, 36, 1183–1196.
138. Stolerman I. P. Colpaert F. C. (1990). The European Behavioral Pharmacology Society. Psychopharmacology, 101, 289–291.
139. Stone R. K. Alvarez W. F. Ellman G. Horn A. C. White J. F. (1989). Prevalence and prediction of psychotropic drug use in California developmental centers. American Journal of Mental Retardation, 93, 627–632.
140. Stores G. (1988). Antiepileptic drugs. In Ed. Aman M. G. Singh N. N. (Eds.), Psychopharmacology of the developmental disabilities (pp. 101–118). New York: Springer-Verlag.
141. Thompson D. M. (1972). Enhancement of progressive-ratio performance by chlordiazepoxide and phenobarbital. Journal of the Experimental Analysis of Behavior, 17, 287–292.
142. Thompson D. M. (1976). Repeated acquisition of behavioral chains: Effects of methylphenidate and imipramine. Pharmacology, Biochemistry, and Behavior, 4, 671–677.
143. Thompson T. (1986). Developmental behavioral pharmacology. In Ed. Krasnegor N. A. Gray D. B. Thompson T. (Eds.), Advances in behavioral pharmacology (vol. 8, pp. 3–20). Hillsdale, NJ: Lawrence Earlbaum.
144. Thompson T. Dews P. B. McKim W. A. (1987). Advances in behavioral pharmacology (vol. 3). New York: Academic Press.
145. Thompson T. Kennedy C. H. (in press). Emerging health issues impacting the problem behavior of people with developmental disabilities. In Ed. Wehmeyer M. Patton J. R. (Eds.), Mental retardation in the 21st century. Austin, TX: ProEd.
146. Thompson T. Schuster C. R. (1968). Behavioral pharmacology. Englewood-Cliffs, NJ: Prentice-Hall.
147. Trimble M. R. Reynolds E. H. (1984). Neuropsychiatric toxicity of anticonvulsant drugs. In Ed. Matthews W. B. Glaser G. H. (Eds.), Recent advances in clinical neurology (vol. 4, pp. 261–280). Edinburgh, UK: Churchill Livingstone.
148. Tseng L. Loh H. H. Li C. H. (1976). β-Endorphin as a potent analgesic by intravenous injection. Nature, 263, 239–240.
149. Verhave T. Owen J. E., Jr. Slater O. H. (1958). Effects of various drugs on escape and avoidance behavior. Progress in Neurobiology, 3, 267–301.
150. Waller M. B. Morse W. H. (1963). Effects of pentobarbital on fixed-ratio reinforcement. Journal of the Experimental Analysis of Behavior, 6, 125–130.
151. Walters A. Singh N. N. Beale I. L. (1977). Effects of lorazepam on hyperactivity in retarded children. New Zealand Medical Journal, 86, 473–475.
152. Wasman M. Flynn J. P. (1962). Directed attack from hypothalamus. Archives of Neurology, 61, 220–227.
153. Watson J. E. Blampied N. M. (1989). Quantification of the effects of chlorpromazine on performance under delayed matching to sample in pigeons. Journal of the Experimental Analysis of Behavior, 51, 317–328.
154. Wei E. Loh H. H. (1976). Physical dependence on opiate-like peptides. Science, 193, 1262–1263.
155. Weissman A. (1959). Differential drug effects upon a three-ply multiple schedule of reinforcement. Journal of the Experimental Analysis of Behavior, 2, 271–287.
156. Wild G. C. Benzel E. C. (1994). Essentials of neurochemistry. Boston: Jones & Bartlett.
157. Williams D. (1969). Neural factors related to habitual aggression. Brain, 92, 503–520.
158. Wise R. A. (1982). Neuroleptics and operant behavior: The anhedonia hypothesis. Behavioral and Brain Sciences, 5, 39–53.
159. Witkin J. M. (1986). Effects of chlorpromazine on fixed-ratio responding: Modification by fixed-interval discriminative stimuli. Journal of the Experimental Analysis of Behavior, 45, 195–206.
160. Woods J. H. Herling S. Young A. M. (1981). Comparison of discriminative and reinforcing stimulus characteristics of morphine-like opioids and two meta-enkephalin analogues. Neuropeptides, 1, 409–419.
161. Zarevics P. H. Setler P. E. (1979). Simultaneous rate-independent assessment of intracranial self-stimulation: Evidence for direct involvement of dopamine in brain reinforcement mechanisms. Brain Research, 169, 499–512.